跳到正文
原文
Medical Xpress·· 2026-10-09AI 评分58

Cochrane综述:药企营销与医生更不适宜、更贵的处方相关

Pharmaceutical company marketing negatively influences prescribing

AI 导读

Cochrane系统综述纳入93项研究,发现药企的销售拜访、赠礼与付费餐食与医生开出更不适宜、更贵且数量更多的处方相关。多数研究来自美国且几乎全部为观察性设计,付费餐食与处方量呈剂量反应关系,医生从阿片类药企获得的酬金越多,越可能开出危险的高剂量。综述作者认为,严格的利益冲突政策可能改善处方适宜性。

正文
Pharmaceutical company marketing negatively influences prescribing
This infographic details the number of meals received in 2014 versus opioid prescribing in 2015, based on Hadland et al. (2018). It visualizes the meals received by physicians and the subsequent prescribing rates. Credit: Peter Homer, Creative Content Producer, Cochrane

Doctors' prescribing habits are heavily influenced by payments, gifts and free meals from pharmaceutical companies, leading to more prescriptions for more expensive, less appropriate drugs, a new Cochrane review finds. This can seriously harm both individual patients and health systems.

Pharmaceutical companies use a variety of strategies to market and promote their drugs. These can include one-on-one visits by sales reps to doctors' offices and hospitals; gifts and payments, including paid meals, travel costs to conferences, entertainment, consulting fees and honoraria for participation on advisory boards; and advertising.

For all new medicines, pharmaceutical companies target prescribers with offers of free meals and other gifts and payments. These payments and gifts lead to prescribing of the company's promoted drug, which may not always be needed or be the most appropriate or affordable medicine for each patient.

Less appropriate prescribing and higher medicine costs

Published in the Cochrane Database of Systematic Reviews, the review included 93 studies involving a number of different study types. Almost all of these studies observed real-world prescribing patterns rather than running controlled experiments. The majority of the studies (88%) came from the United States, in part because the Sunshine Act (2010) requires pharmaceutical companies to publicly report details of all payments to doctors, which are compiled in a publicly searchable and analyzable database.

Analyzing data on millions of prescribers, the authors grouped industry interactions into three distinct categories to examine how each one affects a doctor's prescribing habits. These were advertising and education, gifts and payments, and free samples. The authors also looked at conflict-of-interest policies as a mitigation strategy.

Advertising and education, such as sales rep visits, seemed linked to prescribing that was less clinically suitable and pricier, with fairly strong evidence that it also drove up prescription volume.

The largest and most consistent body of evidence covered gifts and payments. Gifts and payments were also linked to less appropriate prescribing, more prescriptions and probably increased costs.

The evidence was too sparse or weak to draw clear conclusions on free drug samples and whether promotion affects hospitals' approved formularies, although what little exists suggests it might.

"Overall, when doctors have more contact with drug company promotion, prescribing tends to become less appropriate, more frequent and more expensive," says study author Dr. Lisa Bero from the University of Colorado Anschutz in the United States. "This is problematic for a number of reasons and it matters because it directly affects patient care. These less appropriate, more expensive drugs can have fewer benefits or more side effects than alternatives, or simply be unnecessary in the clinical context."

The overprescription of opioids is the most infamous example of pharmaceutical companies' promotion exaggerating benefits and minimizing harms. This review found that even inexpensive meals increased opioid prescribing and that the more payments a doctor received from opioid manufacturers, the more likely they were to prescribe dangerously high opioid doses. The widespread inappropriate overprescribing of opioids has led to an epidemic of addiction and deaths from overdoses.

"Patients should be offered the most appropriate treatment for their condition, based on clinical evidence, not industry marketing," adds Bero. "The opioid crisis in North America was perhaps the most egregious example of inappropriate overprescribing, but this was not an isolated incident. It was high-profile due to the significant harms involved, but the systems that enabled it are unfortunately considered business as usual within the industry. Interactions between pharmaceutical companies and prescribing physicians are widespread, and the harms they cause are rarely so visible."

More meals paid for, more drugs prescribed

Notably, the research shows a clear dose-response relationship between paid-for meals and inappropriate prescriptions. The more meals a doctor received from a company, the more of the company's drug they prescribed. This was true for a range of different types of drugs, from drugs for high blood pressure and cholesterol to antidepressants and opioid painkillers.

The authors also point out that this practice is seen as normal and unproblematic in the medical field.

"It's very common for doctors to receive free meals from companies," says lead author Dr. Barbara Mintzes from the University of Sydney, Australia. "Doctors often think that this is trivial and doesn't influence them, that they can't be bought for the price of a sandwich," but the data shows this is an effective marketing strategy. The more free meals a doctor receives, the more likely they are to prescribe less appropriate or more expensive drugs."

Restricting industry interactions may improve prescribing

Some hospitals and medical centers have rules or institutional restrictions in place, also known as conflict-of-interest policies, to limit how much contact industry reps can have with doctors or what gifts or samples they are allowed to provide. The review found that these can mitigate the negative impact of pharmaceutical industry strategies on doctors' prescribing habits.

"It's encouraging to see that robust conflict-of-interest policies in place tended to be effective," Mintzes says. "The data shows that they probably improve prescribing appropriateness and possibly reduce the number of prescriptions."

While this review found that drug promotion negatively influences prescribing across a broad range of drugs and clinical settings, the authors wish to emphasize that this is not about a few "bad apples," but about improving the system. A key positive finding is that strict conflict-of-interest policies are a way forward.

Publication details

Pharmaceutical industry information and promotional strategies aimed at prescribers, Cochrane Database of Systematic Reviews (2026). DOI: 10.1002/14651858.CD013423.pub3

Journal information: Cochrane Library

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Alexander Pol

Alexander Pol

PhD nano-engineering from Delft University. Published researcher and journal reviewer. Brings scientific insight to content standards. Full profile →

Citation: Pharmaceutical company marketing negatively influences prescribing (2026, October 8) retrieved 8 October 2026 from https://medicalxpress.com/news/2026-10-pharmaceutical-company-negatively.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com